New gel treatment for advanced stomach cancer that has spread
Part of Cancer, Digestive system clinical trials.
This trial tests a new gel called Prospidelong given once into the abdomen during surgery for stomach cancer that has spread to the lining of the belly. The goal is to see if it is safe and works well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stomach cancer that has spread to the lining of your belly (peritoneal cavity) but not into your esophagus.
- Your doctor expects you to live at least 6 more months.
- You are able to care for yourself (ECOG score 0 or 1).
- You do not have any serious untreated infections, liver or kidney failure, or other major health problems that are not controlled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new sequence of treatments for advanced stomach cancer that has spread to the lining of the abdomen. You would first get low-dose radiation, then a combination of immunotherapy, chemotherapy, and a special type of chemotherapy delivered directly into the belly, to see if it can control the cancer and improve quality of life.
This trial tests a combination of treatments for stomach cancer that has spread to the lining of the abdomen. The goal is to see if this approach can shrink or control the cancer, potentially making surgery possible.
This trial tests adding the chemotherapy drug paclitaxel directly into the abdomen (intraperitoneal) along with standard IV chemotherapy for people with stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen. The goal is to see if this combination helps control the cancer better than standard treatment alone.
This trial tests a new drug called CT0494BCP for advanced stomach cancer that has not responded to previous treatments. The drug targets a protein called CLDN18.2, which is found on many stomach cancer cells, and aims to help your immune system fight the cancer.
This trial combines heated chemotherapy directly into the abdomen (HIPEC) with standard chemotherapy and an immunotherapy drug to treat advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial studies a combination treatment for stomach cancer that has spread to the lining of the abdomen. It uses a special way to deliver heated chemotherapy directly into the abdomen, along with an immunotherapy drug that helps your immune system attack the cancer.
Hear when a new Gastric Cancer With Peritoneal Dissemination trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.